Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 5.35M P/E - EPS this Y 98.30% Ern Qtrly Grth -
Income -37.71M Forward P/E -0.40 EPS next Y -5.60% 50D Avg Chg -55.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -97.00%
Dividend N/A Price/Book 0.40 EPS next 5Y - 52W High Chg -100.00%
Recommedations 2.00 Quick Ratio 0.02 Shares Outstanding 4.85M 52W Low Chg 5.00%
Insider Own 0.00% ROA -128.31% Shares Float 4.85M Beta 0.98
Inst Own - ROE - Shares Shorted/Prior 106.97K/46.36K Price 1.89
Gross Margin - Profit Margin - Avg. Volume 989,690 Target Price 500.00
Oper. Margin - Earnings Date Nov 7 Volume 114,133 Change -2.58%
About Panbela Therapeutics, Inc.

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

Panbela Therapeutics, Inc. News
11/14/24 Panbela Provides Business Update and Reports Q3 2024 Financial Results
10/31/24 Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024
09/24/24 First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center
08/13/24 Panbela Provides Business Update and Reports Q2 2024 Financial Results
07/30/24 Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024
06/24/24 Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification
06/10/24 Panbela Announces Oral Presentation at Digestive Disease Week (DDW):
05/15/24 Panbela Provides Business Update and Reports Q1 2024 Financial Results
05/06/24 Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac
05/01/24 Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
04/30/24 Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week
04/22/24 Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
04/18/24 Panbela Announces Poster Presentation at American Association for Cancer Research:
04/16/24 Panbela Announces Transfer to OTCQB Market
03/26/24 Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
03/12/24 Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
02/15/24 Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
02/01/24 Panbela Announces Closing of Approximately $9.0 Million Public Offering
01/30/24 Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
01/29/24 Panbela Announces Pricing of Approximately $9.0 Million Public Offering
PBLA Chatroom

User Image Miok Posted - 2 days ago

$PBLA Net loss in the quarter was approximately $7.2 million, or $1.48 per diluted share, compared to a net loss of $7.8 million, or $53.74 per diluted share, in the same period last year. Total current assets were $5.2 million and current liabilities were $20.1 million as of the same date. Interim analysis still on track for Q1 2025.

User Image Miok Posted - 1 week ago

$PBLA setting up for Next Q.

User Image Miok Posted - 1 week ago

$PBLA fused up to $9m from invester

User Image Miok Posted - 3 weeks ago

$PBLA how is this still trading?

User Image NVDAMillionaire Posted - 3 weeks ago

$PBLA Financials section https://beyondspx.com/article/panbela-therapeutics-inc-pbla-navigating-the-challenges-of-advancing-innovative-therapeutics

User Image DNegs Posted - 10/30/24

$PBLA this keep bouncing to .38….any big dips buy for the never ending .38 bounces.

User Image RamiBrk Posted - 2 months ago

$PBLA any one here lost more than 13k on here ??

User Image RamiBrk Posted - 2 months ago

$PBLA wow this is sad 😔

User Image TimingTimingTiming Posted - 2 months ago

$PBLA sorry you guys fell for this one; you can thank the SEC for doing nothing about known scams

User Image BandG Posted - 3 months ago

$PBLA so bad pipelines? I hope In a buyout

User Image Bhealthy Posted - 3 months ago

$PBLA Did they finally close up shop?

User Image SilentRider1 Posted - 3 months ago

$PBLA or?

User Image SilentRider1 Posted - 3 months ago

$PBLA they are searching for money

User Image Bhealthy Posted - 3 months ago

$PBLA Bankrupt!!

User Image SilentRider1 Posted - 3 months ago

$PBLA or probably yes :(

User Image Haniii1992 Posted - 3 months ago

$PBLA are the companies that have gone bankrupt, which is why you can't buy or sell?

User Image BarclayMullins Posted - 08/29/24

$PBLA wish I had never heard of this pos

User Image MuesLee Posted - 3 months ago

@_diagio thank you. So NASDAQ and NYSE put no limitation on the amount or percentage of dilution? Does US law put limitations on US settled companies? I just ask, as I see companies like $pbla or $kprx, which diluted heavily and in the 16000% or 1000% range. I consider putting a coverage on that issue.

User Image Haniii1992 Posted - 4 months ago

$PBLA It says on Stocks that it costs 1,110, and here it is a different price, can someone tell me why?

User Image Bhealthy Posted - 4 months ago

$PBLA Financials state that they have $59k in cash left!!! Lol Goodbye you scam

User Image DekmarTrades Posted - 4 months ago

HERE ARE ALL OF THE BEST PRESS RELEASES TODAY AND FILINGS! $CING $LTCH $PBLA $AISP $GOVX

User Image Article_AI Posted - 4 months ago

$PBLA H.C. Wainwright Remains a Hold on Panbela Therapeutics (PBLA) H.C. Wainwright analyst Joseph Pantginis maintained a Hold rating on Panbela Therapeutics (PBLA – Research Report) today. The company’s shares clos... https://www.stck.pro/news/PBLA/87092017/

User Image Market_Magician Posted - 4 months ago

$CDT kinda smells like $PBLA OTC bound

User Image BarclayMullins Posted - 4 months ago

$PBLA this been delisted yet?

User Image alrashidi Posted - 4 months ago

$PBLA delisted!!!!

User Image NVDAMillionaire Posted - 4 months ago

$PBLA Panbela Therapeutics, Inc. (PBLA): Navigating the Challenges of Advancing Innovative Therapeutics http://beyondspx.com/2024/07/31/panbela-therapeutics-inc-pbla-navigating-the-challenges-of-advancing-innovative-therapeutics/

User Image DekmarTrades Posted - 07/31/24

HERE ARE THE BEST PRESS RELEASES and FILINGS TODAY! These are always going to be some of the hottest stocks every morning to watch! $NCNC $MHUA are the top two play! $PBLA is now delisted.

User Image BandG Posted - 07/31/24

$PBLA earning reports in august

User Image susu4 Posted - 5 months ago

$PBLA this is completely dead…no dead cat bouncing, it’s just dead

User Image Bigwinner75 Posted - 5 months ago

$PBLA lawsuit anyone

Analyst Ratings
HC Wainwright & Co. Neutral Aug 15, 24
HC Wainwright & Co. Neutral Jun 24, 24
HC Wainwright & Co. Neutral May 16, 24
HC Wainwright & Co. Buy Apr 2, 24
Roth MKM Buy Mar 27, 24
Roth MKM Buy Feb 5, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
GOLDMAN SACHS GROUP INC 10% Owner 10% Owner Nov 08 Sell 0.71 72,874 51,741 397,954 11/13/23